Aimed Alliance submitted a letter in support of Hawaii House Bill 553, which would require health plans to cover biomarker testing for the diagnosis, treatment, management, and ongoing monitoring of diseases. Biomarker testing is a critical tool that enables healthcare providers to collect individualized patient data, facilitating the tailored prevention, diagnosis, and treatment of diseases. Ensuring coverage for biomarker testing is essential to improving accessibility to personalized treatments, ultimately maximizing therapeutic benefits and enhancing patient outcomes. Expanding coverage for biomarker testing will advance medical diagnostics and personalized treatment across medical specialties, ensuring that individuals in Hawaii receive the more effective care. Read the letter here.
Last Updated on March 17, 2025 by Aimed Alliance
